F2RL1 and metabolic dysfunction-associated steatohepatitis: The small molecule 1-PPA is effective in the control of steatosis, inflammation and fibrosis in NASH experimental models through the inhibition of PAR2 activation and of its downstream molecules, like C/EBP-β and SerpinB3, implicated in metabolic alterations and NASH.